Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
Currently predicting for Thu, 16 May 2024

Trading levels for EDIT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 6.35 11.85 %
R2 6.16 8.42 %
R1 6.04 6.31 %
Current price: 5.68
Support S1 5.65 -0.554 %
S2 5.53 -2.67 %
S3 5.33 -6.10 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 6.87 20.95 %
R2 6.72 18.31 %
R1 6.63 16.73 %
Current price 5.68
Support S1 5.56 -2.11%
S2 5.32 -6.34%
S3 5.04 -11.36%

EDIT Predictions History

3 years ago
David King predicted that EDIT for 2021-01-28 is going

Rank:

3 years ago
JS predicted that EDIT for 2021-01-11 is going $88.09 (14.49%)

3 years ago
Xx X predicted that EDIT for 2021-01-11 is going

Rank:

3 years ago
JS predicted that EDIT for 2021-01-05 is going $72.96 (-5.05%)

3 years ago
Brent Ushijima predicted that EDIT for 2021-01-05 is going

Rank:

4 years ago
JS predicted that EDIT for 2020-03-05 is going $24.28 (-3.46%)

4 years ago
Eitan Yehoshua predicted that EDIT for 2020-03-05 is going $24.00 (4.30%)

Rank:

4 years ago
gabitul g predicted that EDIT for 2020-03-05 is going

Rank:

4 years ago
2poJeff predicted that EDIT for 2020-03-05 is going $22.56 (-1.96%)

4 years ago
Johan Oosterbaan predicted that EDIT for 2020-03-05 is going

Rank:
Click to get the best stock tips daily for free!

About Editas Medicine, Inc

Editas Medicine Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic... EDIT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT